Ventripoint Announces Non-Brokered Units Private Placement

Core Viewpoint - Ventripoint Diagnostics Ltd. is conducting a non-brokered private placement to raise up to $500,000 through the issuance of 5,000,000 units at a price of $0.10 per unit, subject to regulatory approval [1][5]. Group 1: Offering Details - Each unit consists of one common share and one common share purchase warrant, with the warrants allowing the purchase of additional shares at $0.13 for 24 months [2]. - The corporation may pay a cash finder's fee and issue finder's warrants up to 8% of the gross proceeds, with each finder's warrant also exercisable at $0.13 for 24 months [3]. - The proceeds from the offering will be allocated to operational costs, sales and marketing, hiring key personnel, and general working capital [4]. Group 2: Regulatory and Compliance Information - All securities issued will be subject to a hold period of four months plus one day from the closing date of the offering [5]. - The securities will not be registered under the U.S. Securities Act of 1933 and cannot be offered or sold in the United States without proper registration or exemption [6]. Group 3: Company Overview - Ventripoint has established itself as a leader in applying AI to echocardiography, with its VMS+ products providing accurate cardiac measurements comparable to MRI [8]. - The technology is a cost-effective alternative that enhances cardiologists' confidence in patient management and is compatible with all ultrasound systems from various vendors, supported by regulatory approvals in the U.S., Europe, and Canada [8].